HBK Investments L P decreased its holdings in Masimo Co. (NASDAQ:MASI) by 54.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,096 shares of the medical equipment provider’s stock after selling 42,350 shares during the quarter. HBK Investments L P owned 0.07% of Masimo worth $3,061,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in the company. Stone Ridge Asset Management LLC bought a new position in Masimo during the fourth quarter valued at about $1,757,000. Deutsche Bank AG boosted its stake in Masimo by 17.4% during the fourth quarter. Deutsche Bank AG now owns 227,863 shares of the medical equipment provider’s stock valued at $19,321,000 after buying an additional 33,843 shares in the last quarter. Fred Alger Management Inc. boosted its stake in Masimo by 9.4% during the fourth quarter. Fred Alger Management Inc. now owns 41,036 shares of the medical equipment provider’s stock valued at $3,480,000 after buying an additional 3,517 shares in the last quarter. Brown Capital Management LLC boosted its stake in Masimo by 0.8% during the fourth quarter. Brown Capital Management LLC now owns 98,506 shares of the medical equipment provider’s stock valued at $8,353,000 after buying an additional 819 shares in the last quarter. Finally, MANA Advisors LLC bought a new position in Masimo during the fourth quarter valued at about $227,000. 82.84% of the stock is owned by institutional investors.
Masimo Co. (NASDAQ:MASI) opened at $86.95 on Friday. Masimo Co. has a 1 year low of $80.69 and a 1 year high of $104.71. The firm has a market capitalization of $4,489.75, a price-to-earnings ratio of 30.83, a P/E/G ratio of 2.28 and a beta of 0.92.
Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported $0.72 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.11. Masimo had a return on equity of 22.75% and a net margin of 16.49%. The business had revenue of $225.20 million during the quarter, compared to analyst estimates of $201.54 million. During the same quarter last year, the company posted $0.46 EPS. Masimo’s revenue for the quarter was up 22.9% on a year-over-year basis. equities research analysts expect that Masimo Co. will post 2.81 earnings per share for the current year.
In related news, EVP Yongsam Lee sold 10,000 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $92.95, for a total value of $929,500.00. Following the completion of the transaction, the executive vice president now owns 79,000 shares in the company, valued at approximately $7,343,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sanford Fitch sold 2,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $93.07, for a total value of $186,140.00. Following the completion of the transaction, the director now owns 68,249 shares of the company’s stock, valued at approximately $6,351,934.43. The disclosure for this sale can be found here. Insiders sold a total of 24,100 shares of company stock valued at $2,186,340 in the last quarter. 16.60% of the stock is currently owned by corporate insiders.
MASI has been the subject of several research reports. Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a research note on Tuesday, March 6th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $91.00 target price on shares of Masimo in a research note on Thursday, March 1st. BidaskClub raised Masimo from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, Barclays initiated coverage on Masimo in a research note on Friday, March 9th. They set an “overweight” rating and a $97.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $101.00.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.